U.S. to Resume Johnson & Johnson COVID-19 Vaccines Despite Rare Blood Clot Risk
U.S. health officials have lifted an 11-day pause on Johnson & Johnson vaccinations following a recommendation by an expert panel.
Advisers to the Centers for Disease Control and Prevention said Friday the benefits of the single-dose COVID-19 shot outweigh a rare risk of blood clots.
Panel members said it’s critical that younger women be told about that risk so they can decide if they’d rather choose another vaccine.
The CDC and Food and Drug Administration agreed. European regulators earlier this week made a similar decision, deciding the clot risk was small enough to allow the rollout of J&J’s shot.
(Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.)